title: Treatment of P190 Bcr/Abl lymphoblastic leukemia cells with inhibitors of the serine/threonine kinase CK2.
authors.forename: S
authors.initials: S
authors.lastname: Mishra
authors.forename: V
authors.initials: V
authors.lastname: Pertz
authors.forename: B
authors.initials: B
authors.lastname: Zhang
authors.forename: P
authors.initials: P
authors.lastname: Kaur
authors.forename: H
authors.initials: H
authors.lastname: Shimada
authors.forename: J
authors.initials: J
authors.lastname: Groffen
authors.forename: Z
authors.initials: Z
authors.lastname: Kazimierczuk
authors.forename: L A
authors.initials: LA
authors.lastname: Pinna
authors.forename: N
authors.initials: N
authors.lastname: Heisterkamp
mesh_terms: D000818:Animals; D001562:Benzimidazoles / Q000494:pharmacology* / Q000627:therapeutic use; D047390:Casein Kinase II / Q000037:antagonists & inhibitors*; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D016044:Fusion Proteins, bcr-abl; D006801:Humans; D007945:Leukemia, Lymphoid / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics; D051379:Mice
chemical_list: C492322:2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole; C475924:4,5,6,7-tetrabromobenzimidazole; D001562:Benzimidazoles; D016044:Fusion Proteins, bcr-abl; D047390:Casein Kinase II